Novonesis Raises 2026 Sales Growth Outlook to 7–8% After 8% H1 Growth

Novonesis posted 8% organic sales growth and a 37.7% adjusted EBITDA margin in H1 2026, lifting its full-year sales growth outlook from 5–7% to 7–8% (source: Novonesis, Aug 19, 2026). Management expects the full-year margin at the high end of 37–38%. The H1 numbers exceeded the company's February guidance, which had factored in currency headwinds following a Q4 2025 sales miss.